Spoken Alpha
ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals develops RNAi therapeutics—medicines that silence disease-causing genes—for rare and prevalent diseases. The company has six approved products including AMVUTTRA and ONPATTRO for transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria, plus two collaborator-commercialized products.
ALNYLAM PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $32.06B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 28, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ALNY.
$ curl https://api.spokenalpha.com/v1/companies/ALNYFAQ
Spoken Alpha indexes ALNY's earnings call transcripts at https://spokenalpha.com/companies/ALNY. Each call links to attributed speakers and parsed analyst Q&A. ALNYLAM PHARMACEUTICALS, INC.'s own investor relations page is at https://investors.alnylam.com/.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) held its most recent earnings call on 2026-07-30, covering fiscal Q2 2026.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-28 | — | $1.68 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $1.21 | $1.44 | -16.0% | $1.29B | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $1.99 | $1.47 | +35.4% | $1.17B | — | — | EODHD |
| Q4 FY2025 | 2026-02-11 | $1.25 | $1.50 | -16.7% | $1.10B | — | — | EODHD |
| Q3 FY2025 | 2025-10-29 | $2.90 | $1.75 | +65.7% | $1.25B | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $0.32 | $0.15 | +100.0% | $773.7M | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $-0.01 | $-0.37 | +97.3% | $594.2M | — | — | EODHD |
| Q4 FY2024 | 2025-02-12 | $0.06 | $-0.14 | +100.0% | $593.2M | — | — | EODHD |
| Q3 FY2024 | 2024-10-30 | $-0.50 | $-0.39 | -28.2% | $500.9M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $0.56 | $-0.69 | +100.0% | $659.8M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.16 | $-0.63 | +74.6% | $494.3M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $-0.77 | $-0.77 | 0.0% | $439.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $1.74 | $-0.96 | +100.0% | $750.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-1.62 | $-1.34 | -20.9% | $318.8M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-1.06 | $-1.43 | +25.9% | $319.3M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-1.68 | $-1.90 | +11.6% | $335.0M | — | — | EODHD |
| Q3 FY2022 | 2022-10-26 | $-1.58 | $-1.38 | -14.5% | $264.3M | — | — | EODHD |
| Q2 FY2022 | 2022-07-27 | $-2.03 | $-1.36 | -49.3% | $224.8M | — | — | EODHD |
| Q1 FY2022 | 2022-04-27 | $-1.49 | $-1.46 | -2.1% | $213.3M | — | — | EODHD |
| Q4 FY2021 | 2022-02-09 | $-1.69 | $-1.26 | -34.1% | $258.5M | — | — | EODHD |
Source: EODHD. ALNY reported actuals as published; sparse fields render as —.